890032-70-9

Upstream product

• 1383805-55-7 C₂₉H₃₁Cl₂N₃O₂ 
• 1383805-60-4 C₂₄H₂₃Cl₂N₃O 
• 1427715-28-3 C₂₄H₂₂BrCl₂N₃ 
• 1383805-58-0 C₂₄H₂₁Cl₂N₃ 

Downstream Products

• 1427714-40-6 C₂₇H₂₄Cl₂N₄ 
• 1427714-47-3 C₂₄H₂₂Cl₂N₆ 
• 1427714-23-5 C₂₅H₂₂Cl₃N₃ 
• 1427714-31-5 C₂₆H₂₅Cl₂N₃ 
• 1427714-38-2 C₂₄H₂₁BrCl₂N₄ 
• 1427714-39-3 C₂₆H₂₄Cl₂IN₃ 
• 1427714-44-0 C₂₂H₂₀Cl₂IN₅ 
• 1427714-46-2 C₂₃H₂₂Cl₂IN₅ 
• 1427714-57-5 C₁₉H₁₉Cl₂N₃O 
• 1097078-88-0 C₁₉H₂₀Cl₂N₄ 
• 1097211-70-5 C₂₇H₂₄Cl₂N₄O 
• 1097078-89-1 C₃₀H₃₂Cl₂N₄O₃ 
• 1097211-04-5 C₂₂H₂₄Cl₂N₂O₄ 
• 1097078-90-4 C₂₇H₂₇Cl₂N₅O₃ 

Relevant academic research and scientific papers

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive

POLYMORPHS OF 3-CHLORO-4[(2R)-2

Polymorphs of 3-chloro-4[(2R)-2-(4-chlorophenyl)-4-[(1R)-1-(4-cyanophenyl)ethyl]-1- piperazinyl]-benzonitrile are disclosed, as well as pharmaceutical compositions comprising said polymorphs, methods of using the polymorphs, and a process for preparing them.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I): Chemical formula should be inserted here as it appears on the abstract in paper form. or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.